Global Biosimilars Market Insights, Size and Growth Forecast To 2027

Global Biosimilars Market- By Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), By Manufacturing (In-house, Contract), By Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease)and By Region (North America, Europe, Asia Pacific, South America, Middle East, & Africa)- Global forecast from 2020-2027.

Published: Apr-2020	Report ID: HLCA2021	Pages: 1 - 250	Formats^*:
Category : Healthcare

The Global Biosimilars market fuel the growth of pharmaceutical industries owing to cost-effectiveness and active ingredients. The Global biosimilars market will anticipate a remarkable CAGR in the forecast period from 2020-2027. A high amount of investment done by the pharmaceutical sector in biosimilars is proving as an innovation in the pharmaceutical industry.

Moreover, the biosimilars are rapidly increasing their penetration in the field of immunological diseases and tumor treatment due to their advantages, such as better efficacy and lower side effects.

Furthermore, biosimilars are cost-effective and majorly used for curing chronic diseases, and they get secure permission for their application. Also, biosimilars are similar patent drugs in terms of safety, efficacy, and immunity. With ongoing funding from the government and investment in R&D has fueled the demand for the global biosimilars market.

Product Overview in the Global Biosimilars Market

Based on the product, the global biosimilars market segmented into Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin. The interferon segment has captured the highest market share in the global biosimilars market in the forecast period from 2020-2027. With the rising geriatric population and increasing chronic diseases, the interferon segment has dominated the biosimilars as they treat the cancers and other diseases in a cost-effective manner.

Manufacturing Overview in the Global Biosimilars Market

Based on the manufacturing, the global biosimilars market bifurcated into In-house, Contract. The in-house part has dominated the market share of the global biosimilars market. In-house manufacturing of biosimilars will help in the reduction of cost and keep every operational and another step-in check and overall reduce the value of the medicines.

Indication Overview in the Global Biosimilars Market

Based on the indication, the global biosimilars market segmented into Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease. The oncology segment has a significant market demand in the global biosimilars market. With rising, biosimilars demand oncology segment will help in curing cancer at minimal cost with the use of oncology.

Region Overview in the Global Biosimilars Market

Based on geography, the global biosimilars market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. The European region is going to bolster the market growth of biosimilars in the global market in the forecast period from 2020-2027. Due to the rising obesity and increasing cases of cancer, diabetics and biosimilars will treat it economically. Therefore, the European region will fuel the market demand for the global biosimilar market.

Global Biosimilars Market: Competitive Landscape

Companies such Pfizer, Sandoz, Biocon, Biogen, Fresenius Kabi AG, Boehringer Ingelheim, Merck KgaA, Mylan, Eli Lilly, Teva Pharmaceutical, Dr. Reddy's Laboratories, Amgen, Celltrion, Samsung Biologics, Amega Biotech, mAbxience, Probiomed, Apotex, Chong Kun Dang, JCR Pharmaceuticals, Gan & Lee Pharmaceuticals, Gedeon Richter, Biocad, Coherus Bioscience, and Stada Arzneimittel AG and others are key players in the global biosimilars market.

1. Research Strategic Development

1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation

2. Research Methodology

2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation

3. Executive Summary

4. Market Insights

4.1. Economic Factor Analysis
4.1.1. Drivers
4.1.2. Trends
4.1.3. Opportunities
4.1.4. Challenges
4.2. Competitors & Product Analysis
4.3. Regulatory Framework
4.4. Company market share analysis, 2019
4.5. Porterâ€™s Five forces analysis
4.6. New Investment Analysis
4.7. PESTEL Analysis

5. Global Biosimilars Market Overview

5.1. Market Size & Forecast, 2016-2027
5.1.1. Demand
5.1.1.1. By Value (USD Million)
5.2. Market Share & Forecast, 2016-2027
5.2.1. By Product
5.2.1.1. Insulin
5.2.1.2. Interferon
5.2.1.3. Etanercept
5.2.1.4. Infliximab
5.2.1.5. Rituximab
5.2.1.6. Glucagon
5.2.1.7. Calcitonin
5.2.2. By Manufacturing
5.2.2.1. In-house
5.2.2.2. Contract
5.2.3. By Indication
5.2.3.1. Oncology
5.2.3.2. Chronic Disease
5.2.3.3. Blood Disorder
5.2.3.4. Autoimmune Disease
5.2.4. By Region
5.2.4.1. Europe
5.2.4.2. North America
5.2.4.3. Asia Pacific
5.2.4.4. South America
5.2.4.5. Middle East & Africa

6. Europe Biosimilars Market Overview

6.1. Europe Biosimilars Size & Forecast, 2016-2027
6.1.1. Demand
6.1.1.1. By Value (USD Million)
6.2. Europe Biosimilars Market Share & Forecast, 2016-2027
6.2.1. By Product
6.2.1.1. Insulin
6.2.1.2. Interferon
6.2.1.3. Etanercept
6.2.1.4. Infliximab
6.2.1.5. Rituximab
6.2.1.6. Glucagon
6.2.1.7. Calcitonin
6.2.2. By Manufacturing
6.2.2.1. In-house
6.2.2.2. Contract
6.2.3. By Indication
6.2.3.1. Oncology
6.2.3.2. Chronic Disease
6.2.3.3. Blood Disorder
6.2.3.4. Autoimmune Disease
6.2.4. By Country
6.2.4.1. Germany
6.2.4.2. UK
6.2.4.3. France
6.2.4.4. Italy
6.2.4.5. Rest of Europe
6.2.5. Company Market Share (Top 3-5)
6.2.6. Economic Impact Study on Europe Biosimilars Market

7. North America Biosimilars Market Overview

7.1. North America Biosimilars Market Size & Forecast, 2016-2027
7.1.1. Demand
7.1.1.1. By Value (USD Million)
7.2. North America Biosimilars Market Share & Forecast, 2016-2027
7.2.1. By Product
7.2.1.1. Insulin
7.2.1.2. Interferon
7.2.1.3. Etanercept
7.2.1.4. Infliximab
7.2.1.5. Rituximab
7.2.1.6. Glucagon
7.2.1.7. Calcitonin
7.2.2. By Manufacturing
7.2.2.1. In-house
7.2.2.2. Contract
7.2.3. By Indication
7.2.3.1. Oncology
7.2.3.2. Chronic Disease
7.2.3.3. Blood Disorder
7.2.3.4. Autoimmune Disease
7.2.4. By Country
7.2.4.1. US
7.2.4.2. Canada
7.2.4.3. Mexico
7.2.5. Company Market Share (Top 3-5)
7.2.6. Economic Impact Study on North America Biosimilars Market

8. Asia Pacific Biosimilars Overview

8.1. Asia Pacific Biosimilars Market Size & Forecast, 2016-2027
8.1.1. Demand
8.1.1.1. By Value (USD Million)
8.2. Asia Pacific Biosimilars Market Share & Forecast, 2016-2027
8.2.1. By Product
8.2.1.1. Insulin
8.2.1.2. Interferon
8.2.1.3. Etanercept
8.2.1.4. Infliximab
8.2.1.5. Rituximab
8.2.1.6. Glucagon
8.2.1.7. Calcitonin
8.2.2. By Manufacturing
8.2.2.1. In-house
8.2.2.2. Contract
8.2.3. By Indication
8.2.3.1. Oncology
8.2.3.2. Chronic Disease
8.2.3.3. Blood Disorder
8.2.3.4. Autoimmune Disease
8.2.4. By Country
8.2.4.1. China
8.2.4.2. India
8.2.4.3. Japan
8.2.4.4. Australia
8.2.4.5. Rest of Asia Pacific
8.2.5. Company Market Share (Top 3-5)
8.2.6. Economic Impact Study on Asia Pacific Biosimilars Market

9. South America Biosimilars Market Overview

9.1. South America Biosimilars Market Size & Forecast, 2016-2027
9.1.1. Demand
9.1.1.1. By Value (USD Million)
9.2. South America Biosimilars Market Share & Forecast, 2016-2027
9.2.1. By Product
9.2.1.1. Insulin
9.2.1.2. Interferon
9.2.1.3. Etanercept
9.2.1.4. Infliximab
9.2.1.5. Rituximab
9.2.1.6. Glucagon
9.2.1.7. Calcitonin
9.2.2. By Manufacturing
9.2.2.1. In-house
9.2.2.2. Contract
9.2.3. By Indication
9.2.3.1. Oncology
9.2.3.2. Chronic Disease
9.2.3.3. Blood Disorder
9.2.3.4. Autoimmune Disease
9.2.4. By Country
9.2.4.1. Brazil
9.2.4.2. Argentina
9.2.4.3. Rest of South America
9.2.5. Company Market Share (Top 3-5)
9.2.6. Economic Impact Study on South America Biosimilars Market

10. Middle East & Africa Biosimilars Market Overview

10.1. Middle East & Africa Biosimilars Market Size & Forecast, 2016-2027
10.1.1. Demand
10.1.1.1. By Value (USD Million)
10.2. Middle East & Africa Biosimilars Market Share & Forecast, 2016-2027
10.2.1. By Product
10.2.1.1. Insulin
10.2.1.2. Interferon
10.2.1.3. Etanercept
10.2.1.4. Infliximab
10.2.1.5. Rituximab
10.2.1.6. Glucagon
10.2.1.7. Calcitonin
10.2.2. By Manufacturing
10.2.2.1. In-house
10.2.2.2. Contract
10.2.3. By Indication
10.2.3.1. Oncology
10.2.3.2. Chronic Disease
10.2.3.3. Blood Disorder
10.2.3.4. Autoimmune Disease
10.2.4. By Country
10.2.4.1. Saudi Arabia
10.2.4.2. UAE
10.2.4.3. South Africa
10.2.4.4. Rest of Middle East & Africa
10.2.5. Company Market Share (Top 3-5)
10.2.6. Economic Impact Study on Middle East & Africa Biosimilars Market

11. Competitor Analysis

11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profile
11.7.1. Pfizer
11.7.2. Sandoz
11.7.3. Biocon
11.7.4. Fresenius Kabi AG
11.7.5. Boehringer Ingelheim
11.7.6. Mylan
11.7.7. Eli Lilly
11.7.8. Teva Pharmaceutical
11.7.9. Dr. Reddy's Laboratories
11.7.10. Amgen
11.7.11. Celltrion
11.7.12. Samsung Biologics
11.7.13. Amega Biotech
11.7.14. mAbxience
11.7.15. Probiomed
11.7.16. Apotex
11.7.17. Gedeon Richter
11.7.18. Biocad
11.7.19. Coherus Bioscience
11.7.20. Stada Arzneimittel AG
11.7.21. Other Prominent Players

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1